In this Review, we explore the transformative potential of decentralized clinical trials (DCTs) in addressing the limitations of traditional randomized controlled trials (RCTs). We highlight the merits of DCTs fostering greater inclusivity, efficiency, and adaptability. We emphasize the challenges of RCTs, including limited participant diversity and logistical barriers, geographical constraints, and mistrust in research institutions, showing how DCTs are preferred in addressing these challenges by utilizing remote digital technologies and community providers to enable broader, more inclusive participation. Furthermore, we underscore the potential of DCTs for democratizing clinical research. We also stress the importance of addressing unresolved challenges, including data security and privacy, remote patient monitoring, and regulatory variations. Research is needed to devise standardized protocols to streamline DCT processes, explore its long-term impacts on patient outcomes, and overcome challenges through equitable stakeholder engagement.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1126/science.adq4994 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multiple Perspectives on the Need for Real-World Evidence to Inform Regulatory and Health Technology Assessment Decision-Making: Scoping Review and Stakeholder Interviews.
Pharmacoepidemiol Drug Saf
January 2025
Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, The Netherlands.
Purpose: Real-world evidence (RWE) is increasingly considered in regulatory and health technology assessment (HTA) decision-making, though perspectives on its relevance may vary. Expanding on a recent review regarding regulatory decisions, this study aimed to identify factors influencing the need for RWE in HTA decision-making, confirm and enrich factors with stakeholder views, and evaluate similarities and differences between regulatory and HTA needs.
Methods: Previous scoping review methodology was used to identify factors influencing the need for RWE in HTA decision-making.
Comparison of smoking behaviors and associated factors between HIV-infected and uninfected men in Guilin, China: a case-control study.
Front Psychol
December 2024
Guilin Tobacco Company of Guangxi Zhuang Autonomous Region, Guilin, China.
Background: Smoking is highly prevalent among HIV-infected individuals and is associated with high morbidity and mortality. Studies on smoking among HIV-infected individuals in China, especially compared to uninfected individuals, are scarce.
Purpose: This study aimed to investigate and compare the prevalence and factors associated with smoking between HIV-infected and uninfected men in Guilin, China.
Trends and Innovations in Wearable Technology for Motor Rehabilitation, Prediction, and Monitoring: A Comprehensive Review.
Sensors (Basel)
December 2024
2AI, School of Technology, IPCA, 4750-810 Barcelos, Portugal.
(1) Background: Continuous health promotion systems are increasingly important, enabling decentralized patient care, providing comfort, and reducing congestion in healthcare facilities. These systems allow for treatment beyond clinical settings and support preventive monitoring. Wearable systems have become essential tools for health monitoring, but they focus mainly on physiological data, overlooking motor data evaluation.
View Article and Find Full Text PDFFederated Learning: Breaking Down Barriers in Global Genomic Research.
Genes (Basel)
December 2024
Genomic Medicine Laboratory UILDM, IRCCS Santa Lucia Foundation, 00179 Rome, Italy.
Recent advancements in Next-Generation Sequencing (NGS) technologies have revolutionized genomic research, presenting unprecedented opportunities for personalized medicine and population genetics. However, issues such as data silos, privacy concerns, and regulatory challenges hinder large-scale data integration and collaboration. Federated Learning (FL) has emerged as a transformative solution, enabling decentralized data analysis while preserving privacy and complying with regulations such as the General Data Protection Regulation (GDPR).
View Article and Find Full Text PDFStakeholder perspectives on facilitators and barriers to implementing a zero-dollar copay program for chronic conditions study.
Health Res Policy Syst
January 2025
Department of Maternal and Child Health, University of North Carolina Chapel Hill School of Global Public Health, Chapel Hill, United States of America.
Background: Type 2 diabetes mellitus (T2D) remains a pressing public health concern. Despite advancements in antidiabetic medications, suboptimal medication adherence persists among many individuals with T2D, often due to the high cost of medications. To combat this issue, Blue Cross and Blue Shield of Louisiana (Blue Cross) introduced the $0 Drug Copay (ZDC) program, providing $0 copays for select drugs.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!